Johnson Matthey Inc.

Anormed, Inc.

Soligenix, Inc.

Other

Johnson Matthey Public Limited Company

Genzyme Corporation

Arbutus Biopharma Corporation

Shire International Licensing B.v.

Johnson Matthey Public Limted Company

Abdera Therapeutics Inc.

Genzyme Global S.à.r.l.

Lee, Jackson

North, John

Rozek, Annett

Abrams, Michael J.

Michael J Abrams

Gary James Bridger

Christen M Giandomenico

Jean F Vollano

Geoffrey W Henson

Ronald Trevor MacFarland

David Aaron Schwartz

Barry A Murrer

Gary B Calandra

Jon A Zubieta

Hal E Broxmeyer

Annett Rozek

Oreola Donini

Gerald E Bossard

David C Dale

Simon P Fricker

Jackson Lee

Owen J Vaughan

John North

James Heyes

Andrew W Millar

Robert C Brooks

Raymond F Schinazi

Craig L Hill

Lorne Ralph Palmer

Adam Judge

Mark Wood

Donald H Picker

Alexander Laurence Mandel

Richard James Holland

Kieu Lam

Edward D Yaworski

Stephen P Reid

Sreenivasan Padmanabhan

Beverly A Teicher

Fontaine C Bradley

Danielle T Frost

Bradley Fontaine

Kieu Mong Lam

Christen M Giadomenico

Chris M Giandomenico

Stefan R Idzan

Richard B Jacobson

Brian R Theobald

Michael E Ultee

Adam Daniel Judge

Emma Jane Cummins

Raja Solomon Viswas

Ronald Trevor Macfarland

David A Schwartz

C David Dale

Dale C David David

Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R, R, Rand Rare defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.

Cationic lipids containing silicon

Described herein are heavy chain antibodies that bind to DLL3 and immunoconjugates of DLL3 heavy chain antibodies useful for cancer therapy.

Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex

Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis 'window' with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Peptides and analogs for use in the treatment of oral mucositis

The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.

Compositions and methods for delivering messenger RNA

Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formulaZ-linker-Z'&#x2003;&#x2003;(1) 

Methods to mobilize progenitor/stem cells

Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.

Use of rare earth compounds for the prevention of kidney stone disease

Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formulaZ-linker-Z' &#x2003;&#x2003;(1) 

Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.

Methods to enhance white blood cell count

New pharmaceutical compositions and pharmaceutical compositions comprising metal complexes have activity against diseases caused by or related to overproduction or localized high concentration of nitric oxide in the body.

Pharmaceutical compositions comprising metal complexes

New pharmaceutical compositions and pharmaceutical compositions comprising metal complexes have activity against diseases caused by or related to overproduction or localised high concentration of nitric oxide in the body.

Growing community of inventors

Glenmore, PA, United States of America

Michael J Abrams